freeze-thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
The first recorded treatment of a patient by electricity was by Johann Gottlob Krüger in 1743. John Wesley promoted electrical treatment as a universal panacea in 1747 but was rejected by mainstream medicine. Giovanni Aldini treated insanity with static electricity from 1823 to 1824. The first recorded medical treatments with electricity in London were in 1767 at Middlesex Hospital in London using a special apparatus. The same apparatus was purchased for St. Bartholomew's Hospital ten years later. Guy's Hospital has a published list of cases from the early 19th century. Golding Bird at Guy's brought electrotherapy into the mainstream in the mid-19th century. In the second half of the 19th century the emphasis moved from delivering large shocks to the whole body to more measured doses, the minimum effective.
Further shell closures beyond the main island of stability in the vicinity of Z = 112–114 may give rise to additional islands of stability. Although predictions for the location of the next magic numbers vary considerably, two significant islands are thought to exist around heavier doubly magic nuclei; the first near 354126 (with 228 neutrons) and the second near 472164 or 482164 (with 308 or 318 neutrons). Nuclides within these two islands of stability might be especially resistant to spontaneous fission and have alpha decay half-lives measurable in years, thus having comparable stability to elements in the vicinity of flerovium. Other regions of relative stability may also appear with weaker proton shell closures in beta-stable nuclides; such possibilities include regions near 342126 and 462154. Substantially greater electromagnetic repulsion between protons in such heavy nuclei may greatly reduce their stability, and possibly restrict their existence to localized islands in the vicinity of shell effects. This may have the consequence of isolating these islands from the main chart of nuclides, as intermediate nuclides and perhaps elements in a "sea of instability" would rapidly undergo fission and essentially be nonexistent. It is also possible that beyond a region of relative stability around element 126, heavier nuclei would lie beyond a fission threshold given by the liquid drop model and thus undergo fission with very short lifetimes, rendering them essentially nonexistent even in the vicinity of greater magic numbers.
King Michał Korybut Wiśniowiecki, a native Pole, was elected to replace John II Casimir in 1669. The Polish–Ottoman War (1672–1676) broke out during his reign, which lasted until 1673, and continued under his successor, John III Sobieski (r. 1674–1696). Sobieski intended to pursue Baltic area expansion (and to this end he signed the secret Treaty of Jaworów with France in 1675), but was forced instead to fight protracted wars with the Ottoman Empire. By doing so, Sobieski briefly revived the Commonwealth's military might. He defeated the expanding Muslims at the Battle of Khotyn in 1673 and decisively helped deliver Vienna from a Turkish onslaught at the Battle of Vienna in 1683. Sobieski's reign marked the last high point in the history of the Commonwealth: in the first half of the 18th century, Poland ceased to be an active player in international politics. The Treaty of Perpetual Peace (1686) with Russia was the final border settlement between the two countries before the First Partition of Poland in 1772. The Commonwealth, subjected to almost constant warfare until 1720, suffered enormous population losses and massive damage to its economy and social structure. The government became ineffective in the wake of large-scale internal conflicts, corrupted legislative processes and manipulation by foreign interests. The nobility fell under the control of a handful of feuding magnate families with established territorial domains.
Sources: en.wikipedia.org
Soon after plants are water-stressed and the roots are deficient in water, a signal moves up to the leaves, causing the formation of ABA precursors there, which then move to the roots. The roots then release ABA, which is translocated to the foliage through the vascular system and modulates potassium and sodium uptake within the guard cells, which then lose turgidity, closing the stomata.
The Japanese attack on Pearl Harbor in December 1941 led to a change in Roosevelt's position. He transformed his trusteeship proposal into a proposal for Four Policemen – the United States, the United Kingdom, the Soviet Union, and China – to enforce the peace after the war for several years while other nations, friend and foe, would be disarmed. Roosevelt made his first references to the Four Policemen proposal in early 1942. This would not preclude the eventual formation of a worldwide organisation of nations "for the purpose of full discussion" provided "management" was left to the Four Policemen. He presented his postwar plans to Soviet foreign minister Vyacheslav Molotov, who had arrived in Washington on May 29 to discuss the possibility of launching a second front in Europe. The President said to Molotov that "he could not visualize another League of Nations with 100 different signatories; there were simply too many nations to satisfy, hence it was a failure and would be a failure". Roosevelt told Molotov that the Big Four must unite after the war to police the world and disarm aggressor states. When Molotov asked about the role of other countries, Roosevelt answered by opining that too many "policemen" could lead to infighting, but he was open to the idea of allowing other allied countries to participate. A memorandum of the conference summarizes their conversation:
Olfactory receptors (ORs), also known as odorant receptors, are chemoreceptors expressed in the cell membranes of olfactory receptor neurons and are responsible for the detection of odorants (for example, compounds that have an odor) which give rise to the sense of smell. Activated olfactory receptors trigger nerve impulses which transmit information about odor to the brain. Vertebrates have a total of four olfactory receptor families: OR, TAAR, V1R/ORA, and V2R/OlfC. This article focuses on the OR family. This consists of members of the rhodopsin-like (class A) G protein-coupled receptors (GPCRs). OR forms the largest multigene family in vertebrates consisting of around 400 genes in humans and 1400 genes in mice. In insects, olfactory receptors are members of an unrelated group of ligand-gated ion channels.
Sources: en.wikipedia.org
Although the concept of equilibrium is widely used across sciences, in the context of chemistry, it arises whenever a number of different states of the chemical composition are possible, as for example, in a mixture of several chemical compounds that can react with one another, or when a substance can be present in more than one kind of phase. A system of chemical substances at equilibrium, even though having an unchanging composition, is most often not static; molecules of the substances continue to react with one another thus giving rise to a dynamic equilibrium. Thus the concept describes the state in which the parameters such as chemical composition remain unchanged over time.
The Decision of the third plenary session of the 18th Central Committee announced "market forces" would begin to play a "decisive" role in allocating resources. This meant that the state would gradually reduce its involvement in the distribution of capital, and restructure state-owned enterprises (SOEs) to allow further competition, potentially by attracting foreign and private sector players in industries previously highly regulated. This policy aimed to address the bloated state sector that had unduly profited from re-structuring by purchasing assets at below-market prices, assets no longer being used productively. However, by 2017, Xi's promise of economic reforms was said to have stalled by external observers. In 2015, the Chinese stock market bubble popped, which led Xi to use state forces to fix it. China's economy has grown under Xi, more than doubling from CN¥54.8 trillion (US$8.7 trillion) in 2012 to CN¥140.2 trillion (US$20.1 trillion) in 2025, while China's nominal GDP per capita increased from CN¥40,431 (US$6,408) in 2012 to CN¥99,665 (US$14,318) in 2025, surpassing the world average in 2021, though growth has slowed from 7.9% in 2012 to 5% in 2025. Xi has increased state control over the economy, voicing support for SOEs, while also supporting the private sector. CCP control of SOEs has increased, while limited steps towards market liberalization, such as increasing mixed ownership of SOEs were undertaken. Under Xi, an increasing number of private companies have established Party branches.
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
== Mechanism of action == The sensitization of pronociceptive pathways in response to opioid treatment appears to involve several pathways. Research thus far has primarily implicated the μ-opioid receptors (MOR) abnormal activation of NMDA receptors in the central nervous system, and long-term potentiation of synapses between nociceptive C fibers and neurons in the spinal dorsal horn.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.